Last reviewed · How we verify
Amfomycin (AMPHOMYCIN)
Amfomycin (generic name: AMPHOMYCIN) is a drug. It is currently FDA-approved.
Amphomycin is a marketed small molecule drug with a key composition patent expiring in 2028. Its mechanism involves interacting with specific biological molecules, though its primary indication and revenue figures are not specified. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | AMPHOMYCIN |
|---|---|
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amfomycin CI brief — competitive landscape report
- Amfomycin updates RSS · CI watch RSS
Frequently asked questions about Amfomycin
What is Amfomycin?
Amfomycin (AMPHOMYCIN) is a Recombinant protein drug.
What is the generic name of Amfomycin?
AMPHOMYCIN is the generic (nonproprietary) name of Amfomycin.
What development phase is Amfomycin in?
Amfomycin is FDA-approved (marketed).
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing